Saudi Biobank, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard - Health Affairs, Riyadh, Saudi Arabia.
Developmental Medicine Department, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard- Health Affairs, Riyadh, Saudi Arabia; KACST-BWH Centre of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia; King Abdulaziz City for Science and Technology (KACST), Saudi Human Genome Project (SHGP), Satellite Lab at King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs (MNG-HA), Riyadh, Saudi Arabia.
Genomics. 2021 Jul;113(4):1733-1741. doi: 10.1016/j.ygeno.2021.04.002. Epub 2021 Apr 7.
Interferon-induced membrane proteins (IFITM) 3 gene variants are known risk factor for severe viral diseases. We examined whether IFITM3 variant may underlie the heterogeneous clinical outcomes of SARS-CoV-2 infection-induced COVID-19 in large Arab population. We genotyped 880 Saudi patients; 93.8% were PCR-confirmed SARS-CoV-2 infection, encompassing most COVID-19 phenotypes. Mortality at 90 days was 9.1%. IFITM3-SNP, rs12252-G allele was associated with hospital admission (OR = 1.65 [95% CI; 1.01-2.70], P = 0.04]) and mortality (OR = 2.2 [95% CI; 1.16-4.20], P = 0.01). Patients less than 60 years old had a lower survival probability if they harbor this allele (log-rank test P = 0.002). Plasma levels of IFNγ were significantly lower in a subset of patients with AG/GG genotypes than patients with AA genotype (P = 0.00016). Early identification of these individuals at higher risk of death may inform precision public health response.
干扰素诱导的膜蛋白(IFITM)3 基因变异是严重病毒病的已知危险因素。我们研究了 IFITM3 变异是否是导致大型阿拉伯人群中 SARS-CoV-2 感染引起的 COVID-19 临床表现异质性的原因。我们对 880 名沙特患者进行了基因分型;93.8%的患者经 PCR 确认为 SARS-CoV-2 感染,涵盖了大多数 COVID-19 表型。90 天的死亡率为 9.1%。IFITM3-SNP,rs12252-G 等位基因与住院(OR=1.65 [95%CI;1.01-2.70],P=0.04)和死亡率(OR=2.2 [95%CI;1.16-4.20],P=0.01)相关。如果携带该等位基因,年龄小于 60 岁的患者的生存率较低(对数秩检验 P=0.002)。与 AA 基因型患者相比,部分 AG/GG 基因型患者的 IFNγ 血浆水平显著降低(P=0.00016)。早期识别这些死亡风险较高的个体,可能有助于制定精准的公共卫生应对措施。